FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217285393> ?p ?o ?g. }

• W3217285393 endingPage "18" @default.
• W3217285393 startingPage "18" @default.
• W3217285393 abstract "Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/- ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable efficacy and safety, whereas the co-infusion of CD19 & CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed." @default.
• W3217285393 created "2021-12-06" @default.
• W3217285393 creator A5003470754 @default.
• W3217285393 creator A5012971683 @default.
• W3217285393 creator A5041339417 @default.
• W3217285393 creator A5046145195 @default.
• W3217285393 creator A5047978597 @default.
• W3217285393 creator A5058330843 @default.
• W3217285393 creator A5068877757 @default.
• W3217285393 creator A5069176236 @default.
• W3217285393 creator A5074232978 @default.
• W3217285393 creator A5082572835 @default.
• W3217285393 creator A5085926317 @default.
• W3217285393 date "2021-11-19" @default.
• W3217285393 modified "2023-09-28" @default.
• W3217285393 title "Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review" @default.
• W3217285393 cites W1580094408 @default.
• W3217285393 cites W1969582706 @default.
• W3217285393 cites W1982967337 @default.
• W3217285393 cites W1984287161 @default.
• W3217285393 cites W1997353354 @default.
• W3217285393 cites W2084647551 @default.
• W3217285393 cites W2092901728 @default.
• W3217285393 cites W2107806760 @default.
• W3217285393 cites W2130997237 @default.
• W3217285393 cites W2172003817 @default.
• W3217285393 cites W2305142474 @default.
• W3217285393 cites W2322790172 @default.
• W3217285393 cites W2343125831 @default.
• W3217285393 cites W2500107307 @default.
• W3217285393 cites W2514418134 @default.
• W3217285393 cites W2595477151 @default.
• W3217285393 cites W2612946884 @default.
• W3217285393 cites W2650689221 @default.
• W3217285393 cites W2760907988 @default.
• W3217285393 cites W2761657464 @default.
• W3217285393 cites W2762392941 @default.
• W3217285393 cites W2773804840 @default.
• W3217285393 cites W2801641802 @default.
• W3217285393 cites W2864786814 @default.
• W3217285393 cites W2886131798 @default.
• W3217285393 cites W2886502012 @default.
• W3217285393 cites W2892311750 @default.
• W3217285393 cites W2895341625 @default.
• W3217285393 cites W2903062212 @default.
• W3217285393 cites W2903225254 @default.
• W3217285393 cites W2903960245 @default.
• W3217285393 cites W2905654445 @default.
• W3217285393 cites W2919051790 @default.
• W3217285393 cites W2922337803 @default.
• W3217285393 cites W2922798588 @default.
• W3217285393 cites W2936551248 @default.
• W3217285393 cites W2953548686 @default.
• W3217285393 cites W2964558232 @default.
• W3217285393 cites W2966873510 @default.
• W3217285393 cites W2969812499 @default.
• W3217285393 cites W2973021197 @default.
• W3217285393 cites W2982584762 @default.
• W3217285393 cites W2988010451 @default.
• W3217285393 cites W2998859344 @default.
• W3217285393 cites W3006385788 @default.
• W3217285393 cites W3012325124 @default.
• W3217285393 cites W3035443948 @default.
• W3217285393 cites W3036279197 @default.
• W3217285393 cites W3037190766 @default.
• W3217285393 cites W3038359909 @default.
• W3217285393 cites W3047553183 @default.
• W3217285393 cites W3076749343 @default.
• W3217285393 cites W3082855561 @default.
• W3217285393 cites W3089727781 @default.
• W3217285393 cites W3118641774 @default.
• W3217285393 cites W3137217625 @default.
• W3217285393 doi "https://doi.org/10.24926/iip.v12i4.4345" @default.
• W3217285393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36033121" @default.
• W3217285393 hasPublicationYear "2021" @default.
• W3217285393 type Work @default.
• W3217285393 sameAs 3217285393 @default.
• W3217285393 citedByCount "1" @default.
• W3217285393 countsByYear W32172853932023 @default.
• W3217285393 crossrefType "journal-article" @default.
• W3217285393 hasAuthorship W3217285393A5003470754 @default.
• W3217285393 hasAuthorship W3217285393A5012971683 @default.
• W3217285393 hasAuthorship W3217285393A5041339417 @default.
• W3217285393 hasAuthorship W3217285393A5046145195 @default.
• W3217285393 hasAuthorship W3217285393A5047978597 @default.
• W3217285393 hasAuthorship W3217285393A5058330843 @default.
• W3217285393 hasAuthorship W3217285393A5068877757 @default.
• W3217285393 hasAuthorship W3217285393A5069176236 @default.
• W3217285393 hasAuthorship W3217285393A5074232978 @default.
• W3217285393 hasAuthorship W3217285393A5082572835 @default.
• W3217285393 hasAuthorship W3217285393A5085926317 @default.
• W3217285393 hasBestOaLocation W32172853931 @default.
• W3217285393 hasConcept C121608353 @default.
• W3217285393 hasConcept C126322002 @default.
• W3217285393 hasConcept C143998085 @default.
• W3217285393 hasConcept C18031839 @default.
• W3217285393 hasConcept C197934379 @default.
• W3217285393 hasConcept C203014093 @default.

• next